123 related articles for article (PubMed ID: 38523576)
1. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
Sinyavskaya L; Meche A; Faucher A; Hlavacek P; Johnson SMA; DiBonaventura M; Vekeman F; Ren J; Schepart A
Curr Med Res Opin; 2024 May; 40(5):789-801. PubMed ID: 38523576
[No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Costa LJ; LeBlanc TW; Tesch H; Sonneveld P; Kyle RP; Sinyavskaya L; Hlavacek P; Meche A; Ren J; Schepart A; Aydin D; Nador G; DiBonaventura MD
Future Oncol; 2024 Feb; ():. PubMed ID: 38415370
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Wang PF; Yee CW; Gorsh B; Zichlin ML; Paka P; Bhak RH; Boytsov N; Khanal A; Noman A; DerSarkissian M; Ferrante S; Duh MS
Leuk Lymphoma; 2023 Feb; 64(2):398-406. PubMed ID: 36408998
[TBL] [Abstract][Full Text] [Related]
5. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.
Ailawadhi S; Romanus D; Shah S; Fraeman K; Saragoussi D; Buus RM; Nguyen B; Cherepanov D; Lamerato L; Berger A
Future Oncol; 2024 May; 20(15):981-995. PubMed ID: 38231002
[TBL] [Abstract][Full Text] [Related]
8. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
[TBL] [Abstract][Full Text] [Related]
9. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A; De La Torre A; White D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; McCurdy A; LeBlanc R; Song K; Mian H; Louzada M; Sebag M; Bergstrom D; Stakiw J; Reiman A; Kotb R; Aslam M; Venner C; Kaedbey R; Gul E; Reece D
Blood Cancer J; 2023 Dec; 13(1):181. PubMed ID: 38065967
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC; Ramasamy K; Weisel K; Abonour R; Hardin JW; Rifkin RM; Ailawadhi S; Terebelo HR; Durie BGM; Tang D; Joshi P; Liu L; Jou YM; Che M; Hernandez G; Narang M; Toomey K; Gasparetto C; Wagner LI; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):112-122. PubMed ID: 36567211
[TBL] [Abstract][Full Text] [Related]
11. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
Costa LJ; Rodriguez-Otero P
Adv Ther; 2024 Apr; ():. PubMed ID: 38642197
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Lim SL; Wellard C; Moore E; Harrison SJ; Hang Q; Ho J; Rajagopal R; Spencer A
Intern Med J; 2024 May; 54(5):773-778. PubMed ID: 38149340
[TBL] [Abstract][Full Text] [Related]
15. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P; Schepart A; Silverstein AR; Petrilla AA; Johnson W; Schroeder A
Future Oncol; 2023 Apr; 19(11):775-787. PubMed ID: 37132520
[TBL] [Abstract][Full Text] [Related]
16. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
Chen W; Liu A; Li L
Adv Ther; 2023 Feb; 40(2):705-717. PubMed ID: 36463561
[TBL] [Abstract][Full Text] [Related]
17. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
18. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Chari A; Romanus D; Palumbo A; Blazer M; Farrelly E; Raju A; Huang H; Richardson P
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):8-17.e16. PubMed ID: 31722839
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
Shah N; Sussman M; Crivera C; Valluri S; Benner J; Jagannath S
Clin Drug Investig; 2021 Mar; 41(3):201-210. PubMed ID: 33598857
[TBL] [Abstract][Full Text] [Related]
20. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Iida S; Nakakoji M; Spanopoulos D; Okazuka K; Parulekar V; Ishida T
Future Oncol; 2022 Nov; ():. PubMed ID: 36331578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
